Accelerating antimalarial drug discovery through collective expertise and resources

Today, the Malaria Drug Accelerator (MalDA) is a consortium of 18 different laboratories who have individually developed and maintained many of the platforms that contribute to early stage anti-malaria drug development including target discovery and validation.

Members

Dr. Gang Liu
Bill & Melinda Gates Foundation
Dr. Elizabeth A. Winzeler
Winzeler Lab at the University of California, San Diego
Dr. Jeremy Burrows
Medicines for Malaria Venture (MMV)
Dr. Dyann F. Wirth
Wirth Lab at Harvard T.H. Chan School of Public Health
Dr. David Fidock
Fidock Lab at Columbia University Irving Medical Center
Dr. Daniel Goldberg
Goldberg Lab at Washington University
Dr. Javier Gamo
GlaxoSmithKline
Dr. Marcus Lee
Lee Lab at Wellcome Sanger Institute
Prof. Jacquin C. Niles
Niles Lab at Massachusetts Institute of Technology
Dr. Nobutaka Kato
The Global Health Drug Discovery Institute
Prof. Ian Gilbert
Wellcome Centre for Anti-Infectives Research (WCAIR), at the University of Dundee
Prof. Manuel Llinás
Llinas Lab at Pennsylvania State University
Prof. Kelly Chibale
Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town
Dr. Koen Dechering
TropIQ Health Sciences
Dr. Case McNamara
Calibr at Scripps Research
Dr. Philip Hipskind
Lgenia
Dr. Thierry Diagana
Novartis Institutes for Biomedical Research

News & Announcements

Read the latest news and announcements from the Malaria Drug Accelerator Consortium and related members.
Read More
alt text?

Phenotype Database

Single nucleotide variants (SNVs) and insertion-deletion events (INDELs) observed in whole genome analysis from various MalDA’s compound selections with shown antimalarial activity can be access in the phenotype database, including a list of peer-reviewed studies in which the compound was a member.
Learn More
alt text

Learn More

Read about MalDA’s mission and approach

Recent Publications